Publicaciones en colaboración con investigadores/as de Odense University Hospital (15)

2023

  1. International randomized trial on the effect of revascularization or optimal medical therapy of chronic total coronary occlusions with myocardial ischemia - ISCHEMIA-CTO trial – rationale and design

    American Heart Journal, Vol. 257, pp. 41-50

2022

  1. Allergen immunotherapy and/or biologicals for IgE-mediated food allergy: A systematic review and meta-analysis

    Allergy: European Journal of Allergy and Clinical Immunology, Vol. 77, Núm. 6, pp. 1852-1862

  2. First-line trifluridine/tipiracil + bevacizumab in patients with unresectable metastatic colorectal cancer: final survival analysis in the TASCO1 study

    British Journal of Cancer, Vol. 126, Núm. 11, pp. 1548-1554

2021

  1. Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma

    European Journal of Cancer, Vol. 158, pp. 156-168

  2. Thin- versus thick-strut polymer-free biolimus-eluting stents: The BioFreedom QCA randomised trial

    EuroIntervention, Vol. 17, Núm. 3, pp. 233-239

2020

  1. Characteristics and treatment regimens across ERS SHARP severe asthma registries

    European Respiratory Journal, Vol. 55, Núm. 1

  2. Trifluridine/tipiracil plus bevacizumab in patients with untreated metastatic colorectal cancer ineligible for intensive therapy: the randomized TASCO1 study

    Annals of Oncology, Vol. 31, Núm. 9, pp. 1160-1168

2018

  1. Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study

    Open Forum Infectious Diseases, Vol. 5, Núm. 1

2017

  1. A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation

    Leukemia and Lymphoma, Vol. 58, Núm. 1, pp. 153-161

  2. Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: A randomized phase III trial - FIRSTANA

    Journal of Clinical Oncology, Vol. 35, Núm. 28, pp. 3189-3197

2015

  1. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  2. Development of a hypoallergenic recombinant parvalbumin for first-in-man subcutaneous immunotherapy of fish allergy

    International Archives of Allergy and Immunology, Vol. 166, Núm. 1, pp. 41-51

2012

  1. Fast: Towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies

    Clinical and Translational Allergy, Vol. 2, Núm. 1

  2. Mortality after surgery in Europe: A 7 day cohort study

    The Lancet, Vol. 380, Núm. 9847, pp. 1059-1065

2010

  1. Pemetrexed safety and pharmacokinetics in patients with third-space fluid

    Clinical Cancer Research, Vol. 16, Núm. 10, pp. 2872-2880